Human methylome studies SRP082156 Track Settings
 
Cancer Associated Fibroblasts are defined by a core set of epigenome changes that contribute to the tumor phenotype [WGBS] [Cancer Associated Fibroblast, Normal Prostate Fibroblast]

Track collection: Human methylome studies

+  All tracks in this collection (424)

Maximum display mode:       Reset to defaults   
Select views (Help):
HMR       PMD       CpG methylation ▾       AMR       CpG reads ▾      
Select subtracks by views and experiment:
 All views HMR  PMD  CpG methylation  AMR  CpG reads 
experiment
SRX2023278 
SRX2023279 
SRX2023280 
SRX2023281 
SRX2023282 
SRX2023283 
SRX2023284 
SRX2023285 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX2023278  CpG methylation  Cancer Associated Fibroblast / SRX2023278 (CpG methylation)   Data format 
hide
 Configure
 SRX2023279  CpG methylation  Cancer Associated Fibroblast / SRX2023279 (CpG methylation)   Data format 
hide
 Configure
 SRX2023280  CpG methylation  Cancer Associated Fibroblast / SRX2023280 (CpG methylation)   Data format 
hide
 Configure
 SRX2023281  CpG methylation  Cancer Associated Fibroblast / SRX2023281 (CpG methylation)   Data format 
hide
 Configure
 SRX2023282  CpG methylation  Normal Prostate Fibroblast / SRX2023282 (CpG methylation)   Data format 
hide
 Configure
 SRX2023283  CpG methylation  Normal Prostate Fibroblast / SRX2023283 (CpG methylation)   Data format 
hide
 Configure
 SRX2023284  CpG methylation  Normal Prostate Fibroblast / SRX2023284 (CpG methylation)   Data format 
hide
 SRX2023285  HMR  Normal Prostate Fibroblast / SRX2023285 (HMR)   Data format 
hide
 Configure
 SRX2023285  CpG methylation  Normal Prostate Fibroblast / SRX2023285 (CpG methylation)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: Cancer Associated Fibroblasts are defined by a core set of epigenome changes that contribute to the tumor phenotype [WGBS]
SRA: SRP082156
GEO: GSE85609
Pubmed: 29650553

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX2023278 Cancer Associated Fibroblast 0.610 6.3 56611 6662.2 67 1288.0 1458 813550.5 0.995 GSM2279670: WGBS CAF1; Homo sapiens; Bisulfite-Seq
SRX2023279 Cancer Associated Fibroblast 0.590 6.2 53081 6515.8 38 1394.0 1436 828116.4 0.983 GSM2279671: WGBS CAF2; Homo sapiens; Bisulfite-Seq
SRX2023280 Cancer Associated Fibroblast 0.615 6.5 54255 6345.4 73 1165.8 1457 830832.4 0.997 GSM2279672: WGBS CAF3; Homo sapiens; Bisulfite-Seq
SRX2023281 Cancer Associated Fibroblast 0.593 5.9 52973 7752.8 61 1212.1 1467 817893.8 0.995 GSM2279673: WGBS CAF4; Homo sapiens; Bisulfite-Seq
SRX2023282 Normal Prostate Fibroblast 0.575 6.3 50555 11344.8 43 1177.2 1807 689500.4 0.996 GSM2279674: WGBS NPF1; Homo sapiens; Bisulfite-Seq
SRX2023283 Normal Prostate Fibroblast 0.611 6.5 51998 6175.0 53 1141.9 1314 936251.0 0.991 GSM2279675: WGBS NPF2; Homo sapiens; Bisulfite-Seq
SRX2023284 Normal Prostate Fibroblast 0.571 6.6 50947 12299.2 87 1159.8 1803 728877.1 0.995 GSM2279676: WGBS NPF3; Homo sapiens; Bisulfite-Seq
SRX2023285 Normal Prostate Fibroblast 0.627 6.8 51526 3784.9 73 1250.9 1375 873064.7 0.995 GSM2279677: WGBS NPF4; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.